

Provider Summary of EAPG Drug Re-Weight Meeting 2/14/2020

Welcome Message and Meeting Etiquette (Slides 1-4, Time 00:00:00-00:01:50)

- Introductions

Screenshare of Data Request Document (Time 00:01:50-00:09:05)

Data Request Document was created by Colorado Hospital Association (CHA) request

Request 1 (Sheet 1) (Time 00:01:50-00:05:30)

Proposed changes in EAPG weights

Request 2 (Sheet 2) (Time 00:05:30-00:06:56)

Cost to Charge Ratios for Cost Center 73 for each Hospital

Request 3 (Sheet 3) (Time 00:06:56-00:09:45)

Aggregate counts by drug EAPG by hospital to the lowest level of detail that can be shared

To protect HIPAA the Department can only share numbers with a count higher than 30.

Stakeholder Question/Comment could not be heard.

Excel Book: Drug Enhanced Ambulatory Patient Groups Reweighting Analysis non-PHI (Time 00:09:45-00:10:00)

Sheet 1: Payment Impact Estimate using CY 18 Data (Time 00:09:45-00:10:47)

Sheet 2: Refreshed Data Estimate (Time 00:10:47-00:16:42)

Switched back and forth slightly from Sheet 2 to Sheet 1

Stakeholder Question with Department Response (Time 00:15:52-00:16:42)

Stakeholder Question: For clarification, that means a shift of \$1.264 million from urban to CAH and Medicare Dependent – annually?

Sheet 1: CY 18 Impact Estimate (Time 00:16:42-00:20:27)

Discussion with CHA

Additional Questions/Comments (Sound quality was limited)

Future plans/ideas

PDF Enhanced Ambulatory Patient Groups Cost Percentile Graphs (Time 00:20:27-00:29:35)

This document focuses more on why we have calculated this change, illustrating proposed hospital groupings and their drug utilization by cost percentile.

Excel Book: Drug Enhanced Ambulatory Patient Groups Reweighting Analysis non-PHI (00:29:35-00:43:24)

Stakeholder Question/Comment – unable to hear due to sound quality

Additional Questions/Comments (Sound quality was limited)

Future plans/ideas

PDF Enhanced Ambulatory Patient Groups Cost Percentile Graphs (Time 00:42:10-00:44:25)

Stakeholder Question: Can you repeat the Y Axis representation again?

Excel Book: Drug Enhanced Ambulatory Patient Groups Reweighting Analysis non-PHI (00:44:25-00:51:10)

PDF Enhanced Ambulatory Patient Groups Cost Percentile Graphs (Time 00:51:10-01:04:09)

Stakeholder Question: This cost is not including the 340B program correct, this is market cost of drugs.

Poll (Time 01:04:09-01:06:43)

1. Do you want more time to consider this proposal?
Results:
 - Yes: 20%
 - No: 80%
2. Are you in favor of the re-weight plan as currently presented?
Results:
 - Yes: 60%
 - No: 20%
 - Neutral/Unsure: 20%
3. Please provide additional comment and/or concern?
 - Kept anonymous

Closing Remarks (Time 01:06:43-01:10:28)